Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. Tumor mutational burden (TMB) is a [[genomic]] [[biomarker]] with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to [[checkpoint inhibitor]]s. ---- It is defined as the number of non-inherited mutations per million bases of investigated genomic sequence, and its measurement has been enabled by next generation sequencing. tumor_mutational_burden.txt Last modified: 2024/06/07 02:57by 127.0.0.1